Here we present technical details that describes mathematical methodologies and analytical derivations used for our results presented in the main text and parameter estimates. In section 1 we present our mathematical model which describes the dynamics of the emergence of acquired and transmitted drugresistant HIV in a population. This is followed by a discussion of the parameters used in the model. We formulate the ordinary differential equations (ODEs) describing the mean-field population dynamics and describe the initial conditions for the model. In section 2 we formulate the dynamics of the drug-resistant population using a Markov chain equation and we discuss the approximations required for this formulation to produce acceptably accurate dynamics. We then show how this can be used to obtain expressions for the evolution of the mean, variance and skewness of the cumulative transmitted resistance.
The mean-field dynamics
In Fig.1 we show the flow diagram of the compartmental Markov chain model that we used to describe the dynamics of the emergence of acquired and transmitted drug-resistant HIV in a population. The model identifies four population groups: sexually-active susceptible adults X, treatment-naive adults infected with wild-type HIV strains Y U S , treated adults infected with wild-type HIV strains Y T S , and adults infected with drug-resistant HIV strains Y R . The drug-resistant group could be subdivided into treated and treatmentnaive classes. In the limit of large population numbers present in all four compartments, the dynamics λ R (t) = N −1 (t)β R Y R (t) , (1.6) We assume that the expected time that an adult acquires new sex partners in Botswana is on average 34 years. This is exactly the difference in years between the upper (49 years) and the lower (15 years) adult age group that we consider. The inflow of at-risk susceptible adults, π, is chosen and calculated such that in the short term the total population is stationary in the absence of HIV. On the assumption that the population growth can be ignored over the short term, we obtained that π is 49,300 per year. The contact rate was found to be 1.76 per year on the assumption that HIV prevalence is constant over the short term.
In a similar way the contact parameter, c, is chosen and calculated such that in the absence of treatment Thus, individuals that are on treatment remain sexually active for longer than individuals that are not on therapy, on average, for an additional 8 years. Since our predictions are valid for the short term to 2009, our results are robust to the values chosen for the average progression time to AIDS. We assumed that the yearly proportion of treated cases suspending ART, g S , in Botswana is 0.1 [4] and that, on average, drug resistance would develop in 3 to 5 years [5, 6, 7, 8, 9] (see the Main Text for further discussion).
The untreated and treated wild-type transmissibility (i.e., fitness) coefficients per partnership (β β T S ) were calculated to be 0.12 and 0.04 respectively [10, 11, 12] . Our values for β U S and β T S are consistent with those used by Wilson et al. [13] for South Africa for a similar drug regiment. We assume that β U S lies in the range 0.1 to 0.15 [11] . We then calculate β T S from β U S using the following expression
where α T is the reduction in HIV transmissibility (i.e., fitness) due to treatment-induced viral load reduction and p S is the fraction of treated individuals infected that achieve viral suppression on ART. Following Wilson et al., the calculation of the drug-resistant transmissibility is obtained using the following expression
where α R is a proportionality constant. Relatively little is known about the fitness of resistant strains of HIV in vivo. In our paper we assumed α R to be 0.25, 0.5 and 1.0 in different scenarios.
An alternative way of obtaining the values for transmissibility is to use the relationship that each logarithmic increase in viral load (w) is associated with an increase in the risk of transmission by a factor of 2.45 [12] . Explicitly, this relationship is formalized as 10) where β(w) and β(ν) are transmissibilities as a function of viral loads w and ν.
The initial conditions
Our model is integrated starting from the initial conditions that no one is on treatment (Y T S (0) = 0). Therefore HIV drug resistance has not developed (Y R (0) = 0). We assume that the HIV-infected wild-type population is at equilibrium with the susceptible population for our initial conditions. These equilibrium population values are given by:
2 Stochastic formulation for the drug-resistant population dynamics
Stochastic vs. Deterministic
The ODEs formulated in section 1.1 can be numerically integrated to obtain the mean-field population evolution. As long as the populations present in each compartment are large, relative stochastic fluctuations are negligibly small. From the discussed initial conditions (Section 1.3), we are assuming that both the treated wild-type and the drug-resistant population begin their dynamics from zero. This means that relative stochastic fluctuations are important in their initial short-term dynamics. However, for the chosen parameters the initial inflow of individuals into the treated wild-type population is much larger than the inflow into the drug-resistant population. Thus, the time for which relative stochastic fluctuations are important is much greater for the drug-resistant population than for the treated wild-type population. Hence, the evolution of the wild-type population can be approximated by its mean-field dynamics at a much earlier time than the evolution of the drug-resistant population. For this reason, the forecast of the short-term dynamics of the drug-resistant population benefits from a stochastic analysis. This analysis provides not only the mean field evolution of the population numbers, but also the evolution of its variability. Our main interest is in the variability present in the prevalence and incidence patterns of the drug-resistant population. We therefore proceed by treating the drug-resistant population stochastically.
A description of the stochastic dynamics is often obtained via computational integration by means of Monte Carlo methods [18] . This would involve identifying the stochastic processes affecting the drug-resistant population dynamics and simulating the evolution discretely starting from the initial conditions. Then, in
order to obtain the variability in the dynamics one would have to average over many independent ensemble realizations of this evolution. An alternative method is to try to solve the stochastic dynamics analytically by formulating and solving a Master equation [15, 16] . This is an attractive method for proceeding as it produces exact equations to predict the variability in the dynamics. In problems in mathematical epidemiology, this
can not always be done as transition rates present in the Master equation formulation are nonlinear functions of the population size. By assuming that the stochastic fluctuations have a predefined distribution (e.g., Gaussian or Log-Normal) this problem can be overcome to give an approximate solution via the method of moment closure [19] . However, in some problems the nonlinear transition rates can be approximated to linear transition rates that remain valid for the time interval of interest. Our stochastic formulation makes use of this latter approximation and we proceed in obtaining expressions for the variability of the dynamics given by time dependent functions of the variance and skewness of the process.
The Master equation
Eq. (1.4) can be used to formulate a birth-death-immigration Master equation [15, 16] for the drug-resistant population:
where P k (t) denotes the probability that Y R (t) = k. The set of equations described by (2.13) can be used to derive other equations describing the evolution of the moments of the probability distribution of Y R (t).
By the standard approach, we multiply Eq.(2.13) throughout by e θk and sum over the k states to obtain the master equation for the moment generating function M (θ, t). In turn, this can be expressed as an equation
for the cumulant generating function defined as K(θ, t) = log[M (θ, t)].
∂K(θ, t)/∂t
14)
The solution to the master equation allows us to extract cumulants of Y R (t):
2 )and the third central moment ( Y R (t) 3 ) are obtained for n = 1, n = 2 and n = 3 respectively. The skewness can be obtained from the third central moment
. The transition rate β R cX(t)/N (t) is not constant and depends on the evolution of Y R (t). Therefore, as in most epidemic models this makes this transition rate in the master equation a nonlinear function of the population size. To proceed we note that our interest is in the early stages of the dynamics when the susceptible population and the HIV-infected wild-type population have only marginally changed from their initial equilibrium values. Therefore, for the chosen parameters, the approximation that X(t)/N (t) stays constant at its equilibrium value is acceptable during the early stage of the evolution.
This approximation is expressed as
Making use of this
1 By comparing the mean evolution of the drug-resistant population predicted by the solution of the Master equation to the mean-field evolution given by solving the ODE (1.4), we find that this approximation produces at most a 9% error (see Sec. 2.5)
at the sixth and final year of the predictions.
approximation allows us to solve for Y T S (t) exactly: .14) analytically. By using the method of characteristics [17] we obtain three equations:
where β = β R c(X/N ) * and γ = (v R +µ). Solving for θ and letting our initial constant characteristic f = θ(0)
we obtain
which can be re-written in the form
Substituting this expression in the equation forK (in (2.17)) gives us
This integral can be evaluated by appropriate substitutions. Finally, we use our initial condition of P k (0) = δ k,YR(0) which gives K(θ, 0) = f Y R (0) and we obtain our solution as
Here, 
Solution for the Mean, Variance and Skewness
By using Eq. (2.15), Eq. (2.21) and our initial condition of no drug-resistant cases (Y R (0) = 0) we obtain all the cumulants of Y R (t). The mean is given by
our second central moment (variance) is given by
and our third central moment is given by
Solution for the Cumulative Incidence
From the solution of the Master equation we can also extract the cumulant generating function for the cumulative incidence of transmitted drug resistance (T (θ, t)). To obtain this we need to solve the following partial differential equation that relates the rate of change in transmitted incidence to the prevalence of drug resistance in the population:
Therefore, the generating function for the cumulative transmitted drug resistance incidence between times t 1 and t 2 is given by:
By taking the first, second and third derivatives of (2.28) with respect to θ and evaluating these at θ = 0 we obtain expressions for the dynamics of the mean, variance and skewness of the cumulative transmitted drug-resistant population in the interval t 2 − t 1 . We use these expressions in our main article to produce the probabilistic forecasts in the growth of the newly infected transmitted drug-resistant population for different parameter sets. In our manuscript we used time intervals t n+1 − t n each equal to three months.
Solution of the Master Equation versus the numerical integration of the ODEs
We mentioned in Sec. 2.1 that in our stochastic formulation we make use of an approximation whereby the nonlinear transition rates describing the infectious process is replaced by a linear transition rate. This approximation will stay valid initially and only for a short period. Therefore, it is of interest to check how the 
